Recent experience with decitabine in MDS

Clinical Advances in Hematology and Oncology

Volumn 5, Issue 2, 2007, Pages 140-

  Kantarjian, Hagop M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE DEACETYLASE INHIBITOR; VALPROIC ACID; VORINOSTAT;

ARTICLE; BLOOD TRANSFUSION; DIARRHEA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; HUMAN; LIVER EXAMINATION; LOW DRUG DOSE; METHYLATION; MORTALITY; MYELODYSPLASTIC SYNDROME; SIDE EFFECT; SURVIVAL RATE;

AZACITIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; HUMANS; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 33947430098     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (2)

1. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
2. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006; 106:1794-1803.